Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø

XClose

Brain Sciences

Home
Menu

New facility will revolutionise research into neurological conditions

11 November 2021

Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø President & Provost Dr Michael Spence, Professor Alan Thompson and colleagues explain how the new centre of excellence for Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø Neuroscience will help revolutionise the development of treatments for neurological diseases.

Professor Alan Thompson
Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø is a global leader in pioneering research into neurological diseases and is one of the world's largest, most productive and highest-impact neuroscience centres.ÌýThe landmark facility at 256 Grays Inn RoadÌýwill form part of a ‘dual hub’ for Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø neuroscience, supporting our existing laboratories at Queen Square.
Ìý

Watch the video

YouTube Widget Placeholder

Ìý

'Breaking ground at a new home for 21st century neuroscience', featuring interviews with:

  • Dr Michael Spence (President & Provost, Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø)
  • Professor Alan Thompson (Pro Vice-Provost for London and Dean of the Faculty of Brain Sciences, Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø)
  • Professor Mike Hanna (Director, Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø Queen Square Institute of Neurology)
  • Dr Hélène Crutzen (Manager, Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø Queen Square Institute of Neurology)
  • Professor Linda Greensmith (Professor of Neuroscience, Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø)
  • Dr Adrian Ivinson (Chief Operating Officer, UK DRI)
  • Dr Chris Turner (Divisional Clinical Director, National Hospital for Neurology and Neurosurgery)
  • Kevin Argent (Director of Estates Development, Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø)

The state-of-the-art facilities will be home to three bodies: the world-leading Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø Queen Square Institute of Neurology; the headquarters of the UK Dementia Research Institute, which is the single biggest investment the UK has ever made in dementia; and the Ïã¸ÛÁùºÏ²ÊÖÐÌØÍøH National Hospital for Neurology and Neurosurgery (NHNN), which is the UK's largest dedicated neurological and neurosurgical hospital.

It will bring together research scientists, clinicians and patients to create a world-class research and treatment environment for conditions including dementia, Alzheimer’s disease, multiple sclerosis, Huntington’s disease, neuromuscular diseases, Parkinson’s disease, motor neuron diseases, stroke and epilepsy.

Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø signed a contract with construction partner ISG to deliver the 17,500m2 state-of-the-art new neuroscience facility, and demolition and construction are now underway with the building due to be completed in 2024.

Earlier this year Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø’s President & Provost was joined by ISG and University College London Hospitals NHS Foundation Trust to break ground at the site on Grays Inn Road.

Related